Compare ZJYL & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZJYL | CCEL |
|---|---|---|
| Founded | 2006 | 1989 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Managed Health Care |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 32.7M |
| IPO Year | 2023 | 1997 |
| Metric | ZJYL | CCEL |
|---|---|---|
| Price | $0.26 | $3.56 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 151.6K | 11.8K |
| Earning Date | 08-20-2025 | 02-27-2026 |
| Dividend Yield | N/A | ★ 11.30% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $22,826,624.00 | ★ $31,747,500.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.07 | ★ N/A |
| Revenue Growth | ★ 13.42 | N/A |
| 52 Week Low | $0.18 | $3.19 |
| 52 Week High | $1.12 | $8.79 |
| Indicator | ZJYL | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 61.42 | 41.77 |
| Support Level | $0.21 | $3.49 |
| Resistance Level | $0.25 | $4.14 |
| Average True Range (ATR) | 0.02 | 0.29 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 89.89 | 35.78 |
Jin Medical International Ltd offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other living aids products to be used by people with disabilities or impaired mobility. The company's products are sold to distributors in both China and overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, and nursing products. Geographically, it generates the majority of its revenue from Japan.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.